Naloxone increases water and electrolyte excretion after water loading in patients with cirrhosis and ascites.
Endogenous opioids may be involved in the pathogenesis of ascites and edema in patients with liver cirrhosis. We administered the opioid antagonist naloxone (5 mg bolus followed by a 0.06 mg/min infusion) to eight male patients with alcoholic cirrhosis and ascites and to five healthy age- and sex-matched control subjects and determined the effects of naloxone on water and electrolyte excretion after a nonsustained water load (20 ml/kg). In comparison with saline vehicle infusion carried out in the same subjects, naloxone administration resulted in a 50% increase in urine output and creatinine clearance and twofold increases in sodium and potassium excretion in patients with cirrhosis. Fractional sodium and potassium excretion, minimal urinary osmolality, plasma vasopressin and aldosterone levels, arterial blood pressure, and heart rate were not affected by naloxone treatment. The diuretic effect of naloxone was not observed in control subjects. Plasma naloxone levels were about six times higher in patients with cirrhosis than in control subjects (probably because of impaired metabolism of the drug) but only a weak correlation was found between drug levels and the degree of diuresis observed. The diuretic effect of naloxone may be related to an increase in glomerular filtration rate, possibly in conjunction with altered tubular reabsorption.
Veterans Affairs Hospital, Hines, IL 60141.
D J
DJ
Leehey
P
P
Gollapudi
A
A
Deakin
R W
RW
Reid
D000368:Aged; D000450:Aldosterone / Q000097:blood; D001201:Ascites / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D001834:Body Water / Q000378:metabolism*; D003401:Creatine / Q000097:blood / Q000493:pharmacokinetics; D004573:Electrolytes / Q000378:metabolism*; D005919:Glomerular Filtration Rate / Q000187:drug effects / Q000502:physiology; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008103:Liver Cirrhosis / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000097:blood / Q000494:pharmacology*; D011188:Potassium / Q000378:metabolism / Q000652:urine; D012964:Sodium / Q000378:metabolism / Q000652:urine; D014667:Vasopressins / Q000097:blood; D014882:Water-Electrolyte Balance / Q000187:drug effects* / Q000502:physiology
D004573:Electrolytes; D014667:Vasopressins; D009270:Naloxone; D000450:Aldosterone; D012964:Sodium; D003401:Creatine; D011188:Potassium